丹参多酚酸盐对稳定性冠心病微循环障碍影响的随机对照试验方案
本研究为随机对照试验方案,计划纳入78例冠状动脉主支狭窄50%至70%、FFR>0.80且IMR>25的稳定性冠心病患者,随机分为丹参多酚酸盐组与安慰剂组。主要终点为首次30分钟治疗后IMR变化,次要终点包括7天后缺血负荷等指标,旨在评估丹参多酚酸盐对冠脉微循环的改善作用。
要点
- 纳入标准:主支狭窄50%至70%、FFR>0.80且IMR>25的稳定性冠心病患者。
- 主要终点为首次30分钟丹参多酚酸盐或安慰剂治疗后IMR变化。
- 丹参多酚酸盐200mg静脉滴注30分钟,后续7天持续给药。
核心结论
- 本试验将首次阐明丹参多酚酸盐对冠脉微循环的改善效应,为高FFR且伴微循环障碍的稳定性冠心病患者提供治疗手段。
研究设计与样本
- 随机对照试验方案,计划纳入78例稳定性冠心病患者,随机分为丹参多酚酸盐组或安慰剂组。
主要发现
- 尚未报告研究结果,方案设定主要终点为首次30分钟治疗后IMR变化。
- 次要终点为7天后经西雅图心绞痛量表、生活质量量表、动态心电图和6分钟步行试验评估的总缺血负荷。
关键数值与推荐
- 入组条件:冠状动脉主支狭窄50%至70%、FFR>0.80且IMR>25。
- 干预方案:丹参多酚酸盐组静脉滴注200mg持续30分钟,后续7天继续给药;安慰剂组给予匹配的0.9%生理盐水。
临床怎么用
- 若验证有效,丹参多酚酸盐可作为高FFR伴冠脉微循环障碍的稳定性冠心病患者的附加治疗选择。
局限性
- 本文为研究方案,尚无实际结果数据;样本量78例,结论需待试验完成后确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obstruction of coronary microcirculation can lead to myocardial ischemia and poor prognosis. Salvianolate exerts cardiovascular protection at cellular levels. However, no studies have confirmed the effect of salvianolate on stable coronary heart disease (CHD) with high fractional flow reserve (FFR) and myocardial microcirculatory disturbances. METHODS/DESIGN: This study will enroll 78 patients who have stable coronary disease with 50 to 70% stenosis in major coronary arteries and whose FFR > 0.80 and index of microcirculatory resistance (IMR) > 25. Patients will be randomly divided into the salvianolate group or the placebo group. After above evaluations, salvianolate 200 mg will be intravenously dripped immediately for the next 30 min and subsequent 7 days in the salvianolate group, and matching 0.9% normal saline will be arranged in the placebo group. IMR will be reevaluated in immediate phase after first 30 min of salvianolate or placebo treatment. The primary end point will be the IMR change in this phase, and the secondary end points will be the total ischemic burden assessed by the Seattle angina scale, quality of life scale, Holter electrocardiography, and 6-min walk test after 7 days before discharge. DISCUSSION: This study will firstly clarify the improvement effect of salvianolate on coronary microcirculation and provide an effective treatment method for stable CHD patients with high FFR and myocardial microcirculatory disturbance. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR1800018772 . Registered on 9 October 2018 and updated on 2 March 2020.
引用
- Li Z, Luan Y, Wang M, et al. Effects of salvianolate on microcirculatory disturbance in patients with stable coronary heart disease: study protocol for a randomized controlled trial. Trials. 2021. PMID: 33685500. doi:10.1186/s13063-021-05099-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。